

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): June 4, 2007 (May 29, 2007)



**CHEMBIO DIAGNOSTICS, INC.**

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other jurisdiction  
of Incorporation)

**0-30379**  
(Commission File Number)

**88-0425691**  
(IRS Employer  
Identification Number)

**3661 Horseblock Road**  
**Medford, NY 11763**  
(Address of principal executive  
offices)

**631-924-1135**  
(Registrant's Telephone Number)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 3.02 Unregistered Sales of Equity Securities.**

- (a) On June 1, 2007 Chembio Diagnostics, Inc., a Nevada corporation (the "Company"), granted Mr. Aromando options to purchase 100,000 shares of the Company's common stock, exercisable at a price of \$.62 per share, which was the closing price of the Company's common stock on the date of grant. All of the options vest on June 1, 2008, provided that Mr. Aromando continues to be employed by the Company. The Company relied on Section 4(2) of the Securities Act of 1933 as the basis for its exemption from registration of this issuance.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements for Certain Officers.**

- (c) On May 29, 2007, the Company appointed Mr. Robert L. Aromando, Jr. to serve as the Company's Senior Vice President, Commercial Operations. Most recently Mr. Aromando was Managing Partner of K Street Associates, LLC, a lobbying and public policy consulting practice he established in 2006 that represents diagnostic and other healthcare companies. From 2001-2006, Mr. Aromando was Vice President of Marketing, Government Affairs and Public Policy for Bracco Diagnostics, a privately held global leader in medical imaging products with over \$1 billion in sales and over 3,000 employees. Mr. Aromando was previously International Marketing Director for Hoffman La Roche (1991-1998), Director of Global Marketing of Covance Corporation (1998-2000), and President of American Bio Medica (2000-2001). In these positions, Mr. Aromando was significantly engaged in point of care diagnostics, primarily in drug testing. Earlier in his career, from 1984 to 1991, Mr. Aromando held sales and marketing positions with Diagnostic Technology and American Home Products, where his experience included the design and implementation of strategic marketing plans, OEM contracts and distribution agreements for a number of infectious disease diagnostic products and platforms.

**ITEM 7.01. Regulation FD Disclosure.**

On May 30, 2007 the Company issued the press release titled "Chembio Appoints Robert L. Aromando, Jr. Senior Vice President, Commercial Operations" included herein as Exhibit 99.1.

**ITEM 9.01. Financial Statements and Exhibits.**

- (d) Exhibits.

99.1 Press Release titled "[Chembio Appoints Robert L. Aromando, Jr. Senior Vice President, Commercial Operations](#)" issued May 30, 2007.

In accordance with General Instruction B.2 of Form 8-K, the information disclosed in Item 7.01 and Exhibit 99.1 attached to this current report on Form 8-K shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing. This current report on Form 8-K does not constitute a determination of whether any information included herein is material.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: June 4, 2007

Chembio Diagnostics, Inc.

By: /s/ Lawrence A. Siebert  
Lawrence A. Siebert  
Chief Executive Officer

---



**ChemBio Appoints Robert L. Aromando, Jr.  
Senior Vice President, Commercial Operations**

May 30, 2007 - Medford, NY - ChemBio Diagnostics, Inc. (OTCBB:CEMI) has appointed Robert L. Aromando as its Senior Vice President, Commercial Operations. Mr. Aromando brings over 30 years of healthcare sales, marketing, business development and government affairs experience to ChemBio. In this new position at ChemBio, Mr. Aromando will lead the implementation of ChemBio's business plan for its recently patented Dual Path Platform (DPP™) point of care technology, and will also oversee all of ChemBio's other sales, marketing and business development activities.

Most recently Mr. Aromando was Managing Partner of K Street Associates, LLC, a lobbying and public policy consulting practice he established in 2006 that represents diagnostic and other healthcare companies. From 2001-2006, Mr. Aromando was Vice President of Marketing, Government Affairs and Public Policy for Bracco Diagnostics, a privately held global leader in medical imaging products with over \$1 billion in sales and over 3000 employees. Mr. Aromando was previously International Marketing Director for Hoffman La Roche (1991-1998), Director of Global Marketing of Covance Corporation (1998-2000), and President of American Bio Medica (2000-2001). In these positions, Mr. Aromando was significantly engaged in point of care diagnostics, primarily in drug testing. Earlier in his career, from 1984-1991, Mr. Aromando held sales and marketing positions with Diagnostic Technology and American Home Products, where his experience included the design and implementation of strategic marketing plans, OEM contracts and distribution agreements for a number of infectious disease diagnostic products and platforms.

Mr. Aromando has a BS in Immunology and Business from Mercy College, and a Wharton Executive Education Certificate. He is a registered lobbyist with the State of New Jersey and the United States House of Representatives and Senate.

Lawrence Siebert, Chairman and CEO of ChemBio, commented: "We welcome Bob Aromando and the broad range of experience that he brings to ChemBio as well as the confidence and enthusiasm he brings to achieving our objectives."

Robert Aromando, Senior Vice President of ChemBio commented: "This is a great opportunity for me personally and I look forward to working with an outstanding team at ChemBio as we bring our new technology to market."

#### ABOUT CHEMBIO

ChemBio Diagnostics, Inc., a developer and manufacturer of rapid diagnostic tests for infectious diseases, is on the frontlines of the global battle against the AIDS pandemic. The Company has received marketing approval from the FDA for its SURE CHECK(R) HIV 1/2 and HIV 1/2 STAT-PAK(TM) rapid tests, marketed in the United States by Inverness Medical Innovations. The Company also manufactures rapid tests for veterinary Tuberculosis and Chagas Disease,

In March 2007 ChemBio was issued a United States patent for the Dual Path Platform (DPP(TM)), a next generation lateral flow platform. DPP has demonstrated significant advantages over currently available lateral flow methods, including increased sensitivity, sample flexibility, and multiplexing capabilities. Further information on the technology is available at <http://www.chembio.com/newtechnologies.html>.

ChemBio contact: Matty Arce [marce@chembio.com](mailto:marce@chembio.com); 632-924-1135 x123